Biotech: Page 3


  • IPO
    Image attribution tooltip
    AndreyPopov via Getty Images

    Why the biopharma ‘IPO playbook’ changed in 2022

    Biopharma IPOs have puttered in 2022, particularly compared to the record-breaking previous year, but they might be set to rebound.

    By Nov. 21, 2022
  • Person using a laptop computer on a mixed color background
    Image attribution tooltip

    TierneyMJ/Shutterstock.com

    Sponsored by ClinicalMind

    Can a formal needs assessment simplify Speaker Bureau compliance?

    In the biopharmaceutical industry, phases of innovation and change are often driven by regulatory action.

    Nov. 21, 2022
  • Artificial intelligence in healthcare
    Image attribution tooltip
    ArtemisDiana via Getty Images

    Is AI just hype or a real revolution in pharma? It’s complicated

    Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

    By Nov. 17, 2022
  • Francisco Barriga and Kaloyan Tsanov of the Sloan Kettering Institute
    Image attribution tooltip
    Permission granted by Memorial Sloan Kettering Cancer Center

    To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

    A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

    By Nov. 16, 2022
  • HLTH conference 2022
    Image attribution tooltip
    Meagan Parrish/PharmaVoice

    #HLTH: ‘Unicorns are real’ — and here’s how they can navigate a challenging biotech market

    Venture capitalists tackle ways companies can stay afloat while the market’s turbulent waters rise.

    By Nov. 15, 2022
  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic

    Profile

    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

    By Alexandra Pecci • Nov. 15, 2022
  • COVID vaccine development
    Image attribution tooltip
    iStock via Getty Images

    4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

    An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

    By Kelly Bilodeau • Nov. 14, 2022
  • washington flag
    Image attribution tooltip
    iStock via Getty Images
    Opinion

    Why the IRA will drive up the country’s drug bill — not lower it

    On the surface, the Inflation Reduction Act is designed to lower drug prices, but its impact on innovation incentives could produce a landscape of new medicines that are costlier for patients.

    By John LaMattina • Nov. 14, 2022
  • Lene Oddershede
    Image attribution tooltip
    Permission granted by Lene Oddershede
    Q&A

    Novo Nordisk’s quantum bet on ‘world changing’ computing

    Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

    By Nov. 10, 2022
  • U.S. economy contracted for second consecutive quarter
    Image attribution tooltip
    Baris-Ozer via Getty Images

    3 ways pharma can weather a recession

    If “winter is coming” in the form of a recession, pharmas can take advantage of an inherent resiliency by crushing these three fundamentals.

    By Nov. 10, 2022
  • Professional headshot of Joe Landolina
    Image attribution tooltip

    Permission granted by Cresilon

    Profile

    This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

    29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

    By Nov. 9, 2022
  • Tier Bryant, 82VS
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: 82VS’s Trier Bryant

    Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

    By Nov. 9, 2022
  • Rami Elghandour headshot
    Image attribution tooltip
    Permission granted by Rami Elghandour
    Profile

    Chasing that ‘Time magazine cover potential’

    Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

    By Alexandra Pecci • Nov. 8, 2022
  • IV infusion
    Image attribution tooltip
    Amornrat Phuchom via Getty Images

    While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

    Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

    By Nov. 8, 2022
  • MRI Brain scan
    Image attribution tooltip
    Stock via Getty Images

    After numerous setbacks, here’s where the Huntington’s pipeline stands

    A look at emerging treatments and where there’s hope for patients.

    By Kelly Bilodeau • Nov. 7, 2022
  • Businessman walking in front of graphs on screen
    Image attribution tooltip

    Image Source Trading Ltd/Shutterstock.com

    Sponsored by CorEvitas

    Real world data: Understanding the scope of EHR and claims data

    Using RWE alongside clinical trial data has the potential to streamline time-to-insight while generating a fuller and more patient-centric view of a given therapy’s efficacy.

    Nov. 7, 2022
  • nerve signals in brain
    Image attribution tooltip
    Stock via Getty Images

    Acumen cruises into the fast lane with novel Alzheimer’s treatment

    The company’s distinct amyloid-beta target, which just won a fast track designation, could give it an edge over the competition.

    By Nov. 3, 2022
  • workplace culture
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Pharma execs on creating a better workplace culture

    Top women execs speak to the leadership skills they are embracing as the industry adjusts to a new normal.

    By Oct. 28, 2022
  • A photo of Biogen's Alzheimer's drug Aduhelm
    Image attribution tooltip
    Permission granted by Biogen

    Riches, rags, riches: Is Biogen the Cinderella of biotechs?

    Biogen and Eisai's new Alzheimer's drug is wowing investigators, and it might help the companies get past previous failures.

    By Oct. 27, 2022
  • Two researchers pipette blue liquid from beaker's to test tubes.
    Image attribution tooltip
    iStock via Getty Images
    Q&A // Biotech Spotlight

    The first company to use Nobel-winning click chemistry in humans is on a mission to transform oncology

    Shasqi founder and CEO José Mejía Oneto on how the company’s approach could provide a more effective alternative to ADCs and other emerging cancer therapies.

    By Oct. 27, 2022
  • Tasuku Kitada head shot
    Image attribution tooltip
    Permission granted by Tasuku Kitada
    Profile

    A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

    The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

    By Alexandra Pecci • Oct. 25, 2022
  • vial therapy
    Image attribution tooltip
    Stock via Getty Images

    Beyond cancer: Scientists push CAR-T cell therapies into new frontiers

    Why a ‘very exciting’ trial of the therapy in lupus patients could swing the door open to new studies in autoimmune diseases.

    By Kelly Bilodeau • Oct. 24, 2022
  • Insomnia in healthcare
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    What’s keeping pharma leaders up at night

    C-suite execs in the life sciences share their late-night thoughts including innovation, patient access and market factors.

    By Oct. 21, 2022
  • Wolly mammoth vintage
    Image attribution tooltip
    Stock illustration via Getty Images
    Profile

    How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development

    Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

    By Alexandra Pecci • Oct. 20, 2022
  • missing target
    Image attribution tooltip
    Stock via Getty Images

    5 impactful drug trial failures from the last year

    Major recent trial flops and what they mean for companies, patients and the industry.

    By Oct. 19, 2022